Give the Bounce Some Room<br />By Rev Shark<br />RealMoney.com Contributor<br />6/9/2010 8:37 AM EDT<br /><br /> "You may be deceived if you trust too much, but you will live in torment if you do not trust enough."<br /><br /> -- Frank Crane <br /><br />Markets don't go straight up or down. During any trend, there will be counter-moves and bounces as oversold or overbought conditions are worked off. The important thing is to not be fooled into thinking that a major trend change is occurring simply because we finally move in the opposite direction for a few days. Bounces are inevitable, but we can't be too trusting of them in the context of a downtrend.<br /><br />The challenge is that counter-trend bounces can easily evolve into a change in character. For example, in March 2009 the Nasdaq put together four positive days in a row after a massive breakdown. Volume wasn't particularly heavy, but we cut through resistance at the 50-day simple moving average and just kept on going. Many bears thought we'd eventually see a retest of the March lows, but it never happened.<br /><br />There wasn't anything technically compelling about the bounce at first, so if you didn't trust it, you missed out on the early gains. Many market players did just that, and that is what then helped to create a wall of worry for the market to climb for the remainder of the year.<br /><br />So here we are now with the market suffering two failed bounces as it has undergone a correction over the past month. We had some positive action in the DJIA and S&P 500 yesterday, and we are we seeing some further gains in the early action this morning. Should we believe that we have seen the lows and load up on longs so that we don't miss the bottom like many did back in March 2009?<br /><br />The answer is that you don't have to believe that we have hit a lasting low in order to take some long positions. There isn't any reason why you can't try to profit from counter-trend moves. You don't need to believe the market is out of the woods, but you should make sure you are disciplined with the way you handle trades. The biggest danger is that the bounce fails and we start to downtrend but you don't cut losses or lock in gains.<br /><br />The biggest problem for momentum and trend traders at this point is that there simply aren't many good charts for that style. There are plenty of things that are oversold and can bounce, but most look like they will eventually be shorts again as they head into resistance levels. There is some room to the upside before major resistance kicks in, so bears should not be in any big rush to reload short positions.<br /><br />There isn't a whole lot of news out there this morning other than some upbeat comments about China exports being 50%-plus over the levels of last May. Tightening in China has been a major concern lately, but this news makes it pretty obvious that those efforts are not doing much to kill that economy.<br /><br />While the market remains technically in a downtrend, the bulls have some positives to work with and a fair amount of room before they run into any big resistance levels. Give the bounce some room, but stay disciplined with your trades. If a major turn does develop, we'll be able to add more exposure down the road as the market proves itself. <br />-----------------------------------<br />Briefing.com vahendusel:<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: MIND +23.3% (light volume), TTWO +4.1%, CIEN +4.0%, OXM +3.1%, TXN +1.4%, light volume).<br /><br />M&A news: DINE +28.8% (Samstock files amended 13D presenting a non-binding indication of interest to acquire for $13.50 per Share in cash), TTIL +19.4% (light volume; TTI Team Telecom to be acquired by TEOCO for $3/share), ECLP +13.5% (Allscripts to acquire Eclipsys for ~$22.10/share in stock .<br /><br />Other news: DEPO +8.8% (very light volume; announces acceptance of new drug application for investigational postherpetic neuralgia treatment DM-1796), DSCO +7.5% (receives FDA guidance regarding preclinical program to gain Surfaxin approval; reports preliminary results from phase 2 clinical trial of Surfaxin), FSII +3.7% (announces pricing of 5.4 mln share public offering of its common stock at $3.05/share), WFT +3.1% (still checking), HCCI +3.1% (prices 3.0 mln common shares at $8.00/share ), POM +2.9% (Cramer makes positive comments on MadMoney), WPPGY +2.2% (still checking), FRX +1.9% (Announces Accelerated Share Repurchase ), DNDN +1.6% (still checking), DO +1.4% (confirms no leaks of oil from ocean saratoga drilling rig).<br /><br />Analyst comments: AVNR +5.9% (initiated with a Buy at Cantor Fitzgerald), VALE +1.9% (upgraded to Buy from Neutral at UBS), POT +1.8% (upgraded to Buy from Neutral at UBS), BIDU +1.8% (initiated with a Buy at ThinkEquity), CHH +0.8% (upgraded to Neutral from Underweight at JP Morgan).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: NCS -3.0%.<br /><br />M&A news: MDRX -3.3% (Allscripts to acquire Eclipsys for ~$22.10/share in stock; also reaffirms 4Q10 and FY10 guidance; sees revenue and non-GAAP EPS at high-end of range).<br /><br />Other news: KGS -5.8% (still checking), REGN -5.7% (reports ARCALYST Phase 3 Trial data), GMR -4.7% (announces agreement to acquire seven modern tankers), FTE -4.4% (trading ex dividend), NOK -3.7% (traded lower overseas), CNP -3.2% (announces 22 mln common stock public offering), TIVO -2.6% (continued weakness following USPTO decision), BP -1.8% (traded lower overseas), WAG -1.0% (CVS Caremark announces plan to remove Walgreens from PBM pharmacy network and transition pharmacy care to participating providers ).<br /><br />Analyst comments: RST -2.7% (downgraded to Neutral from Outperform at Baird),